CPT® Code 90662

Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use

The CPT® Code 90662 refers to a specific formulation of the influenza virus vaccine, which is a split virus, preservative-free vaccine designed for intramuscular use. This vaccine is characterized by its enhanced immunogenicity, achieved through an increased antigen content. Unlike immune globulins that offer short-term, passive immunity, vaccines like this one provide active, long-term immunity. They do so by exposing the recipient's immune system to modified versions of the influenza virus, prompting the immune system to produce its own antibodies. This process enables the body to "remember" how to generate these antibodies upon subsequent exposure to the same virus. The preservative-free aspect of this vaccine indicates that it contains either no thimerosal or only trace amounts, which the FDA recognizes as preservative-free. The vaccine is produced using embryonated chicken eggs, where the virus is harvested, inactivated with formaldehyde, and then concentrated to enhance the antigen content. Following this, the virus undergoes chemical disruption to create a split virus, which is further purified. This particular formulation is especially beneficial for the elderly population, who may have a diminished immune response, making the enhanced immunogenicity crucial for effective vaccination. It is important to note that this code specifically reports the vaccine product itself and does not include the administration of the vaccine, which is billed separately.